Lyra Therapeutics (LYRA) Cash from Financing Activities (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Cash from Financing Activities of -$368000.0 in Q3 2025, down 36700.0% on a QoQ basis from -$1000.0 in Q4 2024, and down 1500.0% YoY from $26285.7 in Q3 2024.
Lyra Therapeutics (LYRA) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Cash from Financing Activities for 7 consecutive years, with -$368000.0 the latest figure, recorded in Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at -$368000.0, down 1500.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$392000.0 (down 104.6% YoY), and the FY2025 annual result was $4.3 million, down 49.91% from the prior year.
- Cash from Financing Activities for Q3 2025 stood at -$368000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $96.5 million in Q2 2022, with the low at -$418000.0 in Q3 2023.
- A 5-year average of $10.7 million and a median of $1500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 216000.0% in 2024 and plunged 1500.0% in 2025, its largest moves.
- Lyra Therapeutics' Cash from Financing Activities stood at -$4000.0 in 2021, then plunged by 5800.0% to -$236000.0 in 2022, then soared by 8116.95% to $18.9 million in 2023, then slumped by 100.01% to -$1000.0 in 2024, then slumped by 36700.0% to -$368000.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$368000.0 (Q3 2025), -$1000.0 (Q4 2024), and -$23000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -368,000.00 |
| Sep 30, 2025 | -368,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Mar 31, 2024 | 8.64 Mn |
| Mar 31, 2024 | 8.64 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Sep 30, 2023 | -418,000.00 |
| Sep 30, 2023 | -418,000.00 |
| Jun 30, 2023 | 47.19 Mn |
| Jun 30, 2023 | 47.19 Mn |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Sep 30, 2022 | -236,000.00 |
| Sep 30, 2022 | -236,000.00 |